Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (71-80 of 323) with videos related to

Pageof 33
Sort By:
Haematologica|February 24, 2018
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|March 4, 2016
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström MacroglobulinaemiaJoshua Gustine, Kirsten Meid, Lian Xu, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 15, 2006
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemiaMarcel N Menke, Gilbert T Feke, J Wallace McMeel, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesSteven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, et al.
American Journal of Hematology|February 24, 2015
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemiaHoury Leblebjian, Kimberly Noonan, Claudia Paba-Prada, et al.
American Journal of Hematology|May 13, 2015
Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER databaseJorge J Castillo, Adam J Olszewski, Sandra Kanan, et al.
Cancer|March 12, 2015
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER databaseJorge J Castillo, Adam J Olszewski, Zachary R Hunter, et al.
American Journal of Hematology|December 9, 2017
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|October 18, 2016
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Zachary R Hunter, et al.
Best Practice & Research. Clinical Haematology|November 10, 2016
Future therapeutic options for patients with Waldenström macroglobulinemiaJorge J Castillo, Zachary R Hunter, Guang Yang, et al.
Pageof 33

Showing results (71-80 of 323) with videos related to

Sort By:
Pageof 33
Haematologica|February 24, 2018
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|March 4, 2016
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström MacroglobulinaemiaJoshua Gustine, Kirsten Meid, Lian Xu, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 15, 2006
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemiaMarcel N Menke, Gilbert T Feke, J Wallace McMeel, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesSteven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, et al.
American Journal of Hematology|February 24, 2015
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemiaHoury Leblebjian, Kimberly Noonan, Claudia Paba-Prada, et al.
American Journal of Hematology|May 13, 2015
Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER databaseJorge J Castillo, Adam J Olszewski, Sandra Kanan, et al.
Cancer|March 12, 2015
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER databaseJorge J Castillo, Adam J Olszewski, Zachary R Hunter, et al.
American Journal of Hematology|December 9, 2017
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|October 18, 2016
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Zachary R Hunter, et al.
Best Practice & Research. Clinical Haematology|November 10, 2016
Future therapeutic options for patients with Waldenström macroglobulinemiaJorge J Castillo, Zachary R Hunter, Guang Yang, et al.
Pageof 33